BIG 4-11/BO25126/TOC4939G | Maryland Oncology Hematology BIG 4-11/BO25126/TOC4939G – Maryland Oncology Hematology

BIG 4-11/BO25126/TOC4939G

Trial Information

A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer



Sponsor: F. Hoffmann-La Roche Ltd and Genentech, Inc.

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Breast Cancer

Investigator

O'Connor

Sponsor

F. Hoffmann-La Roche Ltd and Genentech, Inc.
« Clinical Trails Main

Quality Care Close to Home

View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology